JOP20210029A1 - تركيبات زيتية موضعية - Google Patents

تركيبات زيتية موضعية

Info

Publication number
JOP20210029A1
JOP20210029A1 JOP/2021/0029A JOP20210029A JOP20210029A1 JO P20210029 A1 JOP20210029 A1 JO P20210029A1 JO P20210029 A JOP20210029 A JO P20210029A JO P20210029 A1 JOP20210029 A1 JO P20210029A1
Authority
JO
Jordan
Prior art keywords
oleaginous compositions
topical
topical oleaginous
compositions
useful
Prior art date
Application number
JOP/2021/0029A
Other languages
English (en)
Inventor
Sujit Kumar Dolai
Basant Amarji
Nv Anil Kumar Ravipati
Pradip Kumar Sasmal
Ujjawal Bairagi
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of JOP20210029A1 publication Critical patent/JOP20210029A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

غير متوفر
JOP/2021/0029A 2018-08-16 2019-08-05 تركيبات زيتية موضعية JOP20210029A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841009717 2018-08-16
PCT/IB2019/000737 WO2020035729A1 (en) 2018-08-16 2019-08-05 Topical oleaginous compositions

Publications (1)

Publication Number Publication Date
JOP20210029A1 true JOP20210029A1 (ar) 2021-02-14

Family

ID=68296536

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0029A JOP20210029A1 (ar) 2018-08-16 2019-08-05 تركيبات زيتية موضعية

Country Status (13)

Country Link
US (1) US20200054654A1 (ar)
JP (1) JP2021534161A (ar)
KR (1) KR20210045987A (ar)
CN (1) CN112566623A (ar)
AU (1) AU2019322315A1 (ar)
BR (1) BR112021002656A2 (ar)
CA (1) CA3107702A1 (ar)
CO (1) CO2021003103A2 (ar)
EA (1) EA202190261A1 (ar)
IL (1) IL280810A (ar)
JO (1) JOP20210029A1 (ar)
MX (1) MX2021001209A (ar)
WO (1) WO2020035729A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020055773A (ja) * 2018-10-02 2020-04-09 岩城製薬株式会社 油性外用液
EP3999032A4 (en) 2019-07-16 2023-08-30 Donaghys Limited TRANSDERMAL SOLVENT SYSTEM AND METHOD OF USE
US11890263B2 (en) * 2020-08-13 2024-02-06 Johnson & Johnson Consumer Inc. Methods and compositions suitable for the treatment of acne
CN114028325B (zh) * 2021-12-10 2023-08-01 福元药业有限公司 一种他克莫司软膏制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012783A1 (en) * 1991-12-27 1993-07-08 Kureha Chemical Industry Co., Ltd. Oleaginous ointment
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JP5060561B2 (ja) * 2007-08-17 2012-10-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規外用剤
ES2478845T3 (es) * 2008-10-08 2014-07-23 Takata Seiyaku Co., Ltd. Preparación de tacrolimus para aplicaciones externas
GB201118193D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to oranic compounds
KR101462474B1 (ko) * 2013-10-30 2014-11-19 주식회사 큐리언트 질레우톤 크림 제형의 국소용 항염증 약학적 조성물

Also Published As

Publication number Publication date
IL280810A (en) 2021-04-29
CA3107702A1 (en) 2020-02-20
EA202190261A1 (ru) 2021-07-06
US20200054654A1 (en) 2020-02-20
BR112021002656A2 (pt) 2021-05-11
CO2021003103A2 (es) 2021-04-08
KR20210045987A (ko) 2021-04-27
JP2021534161A (ja) 2021-12-09
MX2021001209A (es) 2021-04-12
WO2020035729A1 (en) 2020-02-20
CN112566623A (zh) 2021-03-26
AU2019322315A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JOP20210029A1 (ar) تركيبات زيتية موضعية
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
GEP20227443B (en) Magl inhibitors
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
CR20190537A (es) Inhibidores pirazólicos de magl
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MY193312A (en) Topical formulation for promoting wound healing
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
MX2020009813A (es) Composiciones y metodos para tratar el prurito.
PE20200749A1 (es) Moduladores de la expresion de enac
CL2022001377A1 (es) Compuestos agonistas de tlr7, composiciones y uso para tratar cáncer y enfermedades infecciosas.
MX2022006903A (es) Productos orales con irritacion reducida.
BR112022003768A2 (pt) Compostos inibidores de perk